• Correction

    Mar 1, 2019, 00:00

  • Use of Both Qualitative and Quantitative Methods to Estimate Meaningful Change Thresholds for Key Endpoints in Pediatric Asthma Trials

    Mar 1, 2019, 00:00

  • Choice of Prosthetic Implant Combinations in Total Hip Replacement: Cost-Effectiveness Analysis Using UK and Swedish Hip Joint Registries Data

    Mar 1, 2019, 00:00

  • Editorial Board

    Feb 1, 2019, 10:11

  • Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease

    Feb 1, 2019, 00:00

  • The Cost-Effectiveness of Financial Incentives for Viral Suppression- HPTN 065 Study

    Feb 1, 2019, 00:00

  • The Internal Validity of Discrete Choice Experiment Data- A Testing Tool for Quantitative Assessments [Editor's Choice]

    Feb 1, 2019, 00:00

  • Association between Disability, Cognition, Fatigue, EQ-5D-3L Domains, and Utilities Estimated with Different Western European Value Sets in Patients with Multiple Sclerosis

    Feb 1, 2019, 00:00

  • Table of Contents

    Feb 1, 2019, 00:00

  • Copyright/Subscription

    Feb 1, 2019, 00:00

  • Estimating CHU-9D Utility Scores from the WAItE- A Mapping Algorithm for Economic Evaluation

    Feb 1, 2019, 00:00

  • Economic Evaluation of Stem Cell Therapies in Neurological Diseases- A Systematic Review

    Feb 1, 2019, 00:00

  • Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women

    Feb 1, 2019, 00:00

  • Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

    Feb 1, 2019, 00:00

  • Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs [Editor's Choice]

    Feb 1, 2019, 00:00

  • A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016)

    Feb 1, 2019, 00:00

  • Methods for Measuring Multiple Medication Adherence- A Systematic Review–Report of the ISPOR Medication Adherence and Persistence Special Interest Group

    Feb 1, 2019, 00:00

  • Equity Weights for Socioeconomic Position- Two Methods—Survey of Stated Preferences and Epidemiological Data

    Feb 1, 2019, 00:00

  • Perceptions of Response Burden Associated with Completion of Patient-Reported Outcome Assessments in Oncology [Editor's Choice]

    Feb 1, 2019, 00:00

  • Paying Low-Income Smokers to Quit? The Cost-Effectiveness of Incentivizing Tobacco Quit Line Engagement for Medicaid Recipients Who Smoke

    Feb 1, 2019, 00:00

  • Comparison of Recommendations and Use of Cardiovascular Risk Equations by Health Technology Assessment Agencies and Clinical Guidelines

    Feb 1, 2019, 00:00

  • Response to letter to the editor related to the retraction of a trial included in a meta-analysis of interventions to enhance oral medication adherence titled “Effectiveness and content analysis of interventions to enhance oral antidiabetic ...

    Feb 1, 2019, 00:00

  • The Retraction of a Trial Included in a Meta-Analysis of Interventions to Enhance Oral Medication Adherence

    Feb 1, 2019, 00:00

  • Market Consolidation and Mortality in Patients Initiating Hemodialysis

    Jan 1, 2019, 00:00

  • Effect of Health State Sampling Methods on Model Predictions of EQ-5D-5L Values: Small Designs Can Suffice

    Jan 1, 2019, 00:00

  • Instructions for Authors

    Jan 1, 2019, 00:00

  • The EQ-5D and the EuroQol Group

    Jan 1, 2019, 00:00

  • Identifying Patients With Relapsing-Remitting Multiple Sclerosis Using Algorithms Applied to US Integrated Delivery Network Healthcare Data

    Jan 1, 2019, 00:00

  • Table of Contents

    Jan 1, 2019, 00:00

  • EQ-5D-Y as a Health-Related Quality of Life Instrument for Children and Adolescents: The Instrument's Characteristics, Development, Current Use, and Challenges of Developing Its Value Set

    Jan 1, 2019, 00:00

  • Pediatric Quality of Life Instruments in Oral Health Research: A Systematic Review

    Jan 1, 2019, 00:00

  • Correspondence

    Jan 1, 2019, 00:00

  • Future Directions in Valuing Benefits for Estimating QALYs: Is Time Up for the EQ-5D?

    Jan 1, 2019, 00:00

  • Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?

    Jan 1, 2019, 00:00

  • Physical Activity and Risk of Breast Cancer: A Meta-Analysis of 38 Cohort Studies in 45 Study Reports

    Jan 1, 2019, 00:00

  • Medical Nutrition Terminology and Regulations in the United States and Europe—A Scoping Review: Report of the ISPOR Nutrition Economics Special Interest Group

    Jan 1, 2019, 00:00

  • Copyright/Subscription

    Jan 1, 2019, 00:00

  • Assessing Emotional Functioning with Increased Power: Relative Validity of a Customized EORTC Short Form in the International ACTION Trial

    Jan 1, 2019, 00:00

  • Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA [Editor's Choice]

    Jan 1, 2019, 00:00

  • Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter? [Editor's Choice]

    Jan 1, 2019, 00:00

  • Selecting Bolt-On Dimensions for the EQ-5D: Examining Their Contribution to Health-Related Quality of Life

    Jan 1, 2019, 00:00

  • Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol [Editor's Choice]

    Jan 1, 2019, 00:00

  • Alternative Weighting Approaches for Anchored Matching-Adjusted Indirect Comparisons via a Common Comparator

    Jan 1, 2019, 00:00

  • Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping

    Dec 1, 2018, 00:00

  • Realizing the “Great Potential” of MCDA in HTA

    Dec 1, 2018, 00:00

  • Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout- Application of a Linked Pharmacometric/Pharmacoeconomic Model

    Dec 1, 2018, 00:00

  • Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease

    Dec 1, 2018, 00:00

  • Cost-Effectiveness of a Comprehensive Approach for Hypertension Control in Low-Income Settings in Argentina- Trial-Based Analysis of the Hypertension Control Program in Argentina

    Dec 1, 2018, 00:00

  • Prediction of Drug-Related Risks Using Clinical Context Information in Longitudinal Claims Data

    Dec 1, 2018, 00:00

  • Table of Contents

    Dec 1, 2018, 00:00

  • Performance of a Bayesian Approach for Imputing Missing Data on the SF-12 Health-Related Quality-of-Life Measure

    Dec 1, 2018, 00:00

  • Important Group Differences on the Functional Assessment of Cancer Therapy–Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma

    Dec 1, 2018, 00:00

  • Copyright/Subscription

    Dec 1, 2018, 00:00

  • A Rights-Based Approach for Service Providers to Measure the Quality of Life of Children with a Disability

    Dec 1, 2018, 00:00

  • Time Is Money- Investigating the Value of Leisure Time and Unpaid Work

    Dec 1, 2018, 00:00

  • Does Inclusion of Interactions Result in Higher Precision of Estimated Health State Values?

    Dec 1, 2018, 00:00

  • A Method for Approximating Future Entry of Generic Drugs

    Dec 1, 2018, 00:00

  • Editorial Board

    Nov 29, 2018, 18:06

  • Copyright/Subscription

    Nov 26, 2018, 17:43

  • Table of Contents

    Nov 1, 2018, 00:00

  • Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States- The Impact of Wording and Perspective

    Nov 1, 2018, 00:00

  • Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non–Small Cell Lung Cancer

    Nov 1, 2018, 00:00

  • Calculating the Expected Value of Sample Information Using Efficient Nested Monte Carlo- A Tutorial

    Nov 1, 2018, 00:00

  • A Systematic Review of Patient-Reported Satisfaction with Oral Medication Therapy in Patients with Type 2 Diabetes

    Nov 1, 2018, 00:00

  • Predictors of Drug Shortages and Association with Generic Drug Prices- A Retrospective Cohort Study

    Nov 1, 2018, 00:00

  • Editorial Board

    Nov 1, 2018, 00:00

  • General Population Norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale

    Nov 1, 2018, 00:00

  • Assessing Lung Cancer Screening Programs under Uncertainty in a Heterogeneous Population

    Nov 1, 2018, 00:00

  • Health State Values Derived from People with Multiple Sclerosis for a Condition-Specific Preference-Based Measure- Multiple Sclerosis Impact Scale–Eight Dimensions–Patient Version (MSIS-8D-P)

    Nov 1, 2018, 00:00

  • Psychometric Evaluation of the Patient’s Knee Implant Performance Questionnaire

    Nov 1, 2018, 00:00

  • Time Trade-Off Value Set for EQ-5D-3L Based on a Nationally Representative Chinese Population Survey

    Nov 1, 2018, 00:00

  • Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease

    Nov 1, 2018, 00:00

  • Editorial Board

    Oct 11, 2018, 13:00

  • PCV6 - SACUBITRIL/VALSARTAN IN HEART FAILURE- PROJECTED HEALTH OUTCOMES IN PORTUGAL

    Oct 1, 2018, 00:00

  • PIN120 - VARIATIONS IN RABIES VACCINE ADMINISTRATION AMONG RABIES EXPOSURE AND BITE VISITS IN UNITED STATES EMERGENCY DEPARTMENT SETTINGS

    Oct 1, 2018, 00:00

  • PIN30 - AN ECONOMIC MODEL TO ESTIMATE THE COST-EFFECTIVENESS OF TRIVALENT INFLUENZA VACCINE HIGH DOSE FOR THE ELDERLY POPULATION IN ENGLAND AND WALES

    Oct 1, 2018, 00:00

  • PHP153 - KEY STAKEHOLDERS PERCEPTIONS OF HEOR USAGE IN LEBANON

    Oct 1, 2018, 00:00

  • PSY131 - ACCESS TO ORPHAN DRUGS (OD) IN SPAIN- ANALYSIS OF NUSINERSEN’S CASE

    Oct 1, 2018, 00:00

  • PMS39 - THRESHOLD PRICES FOR IMPROVEMENTS IN KNEE AND HIP REPLACEMENT- EVIDENCE FROM ROUTINELY COLLECTED DATA

    Oct 1, 2018, 00:00

  • PMH27 - RETROSPECTIVE HEALTHCARE CLAIMS DATA ANALYSIS FOR CHILDREN/ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER RECEIVING SECOND-LINE PHARMACOTHERAPY IN GERMANY, EVALUATING PATIENT CHARACTERISTICS AND HEALTHCARE COSTS

    Oct 1, 2018, 00:00

  • PND66 - COST EFFECTIVENESS ANALYSIS OF ALEMTUZUMAB AS A TREATMENT OPTION FOR PATIENTS WITH MULTIPLE SCLEROSIS IN CYPRUS

    Oct 1, 2018, 00:00

  • PMD57 - HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH AND WITHOUT INFECTION AFTER INTRAMEDULLARY NAILING FOR A TIBIAL SHAFT FRACTURE IN ENGLAND

    Oct 1, 2018, 00:00

  • PUK7 - ASSOCIATION BETWEEN ADHERENCE TO RENIN-ANGIOTENSIN-ALDOSTERONE-SYSTEM (RAAS) INHIBITORS AND RENAL FUNCTION AMONG PATIENTS WITH TYPE 2 DIABETES- A POPULATION BASED STUDY USING REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PHP196 - DEVELOPMENT STRATEGIES PROMOTING PHARMACEUTICAL INDUSTRY TO IMPROVE HEALTHCARE MANAGEMENT

    Oct 1, 2018, 00:00

  • PCV130 - VALUE OF IMPLEMENTATION OF PHARMACEUTICAL CARE FOR CARDIOVASCULAR DISEASES IN LMICS- A HYPOTHETICAL SIMULATION FOR DECISION MAKING

    Oct 1, 2018, 00:00

  • PSY159 - COMPARISON OF ORPHAN DRUG PRICES- BELGIUM VS LUXEMBOURG

    Oct 1, 2018, 00:00

  • DB4 - COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN ADULT PATIENTS WITH INADEQUATELY CONTROLLED TYPE 1 DIABETES- A HEALTH ECONOMIC ANALYSIS USING 24-WEEK RESULTS FROM THE DEPICT-1 RANDOMISED CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PRM75 - DEVELOPMENT OF MACHINE LEARNING BASED ABSTRACT DOCUMENT CLASSIFICATION FOR SUPPORTING SYSTEMATIC REVIEWS

    Oct 1, 2018, 00:00

  • PRM38 - HOW MUCH IS YOUR LIFE WORTH? DEFINING WHAT THE WILLINGNESS TO PAY FOR A QALY IS AND SHOULD BE

    Oct 1, 2018, 00:00

  • PCN359 - COMPARISON OF INSTITUTIONAL AND HOME HOSPICE CARE

    Oct 1, 2018, 00:00

  • PHP95 - THE STUDY OF DYNAMIC ADJUSTMENT MECHANISM OF MEDICAL SERVICE PRICE IN CHINA

    Oct 1, 2018, 00:00

  • PCN5 - TREATMENTS OF RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER IN ROUTINE CLINICAL PRACTICE – A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PDB102 - THERAPY ADJUSTMENT FOLLOWING DPP-4 INHIBITOR INITIATION IN T2DM PATIENTS WITH CREATININE CLEARANCE 50 ML/MIN- A RETROSPECTIVE COHORT STUDY USING DATA FROM UK GENERAL PRACTICE

    Oct 1, 2018, 00:00

  • PIH35 - HTTPS-//ISPOR.CONFEX.COM/ISPOR/EURO21/RESEARCH/PAPERS/INDEX.CGI?USERNAME=85228PASSWORD=173196

    Oct 1, 2018, 00:00

  • PGI37 - UNIVERSAL ACCESS TO DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C MANAGED BY THE HOSPITAL PHARMACY- CONTRIBUTIONS TO PUBLIC HEALTH AND PUBLIC EXPENDITURE

    Oct 1, 2018, 00:00

  • PCN218 - PERSONALIZED THERAPY DEVELOPMENT IN NSCLC DEMONSTRATES INTERSECTION BETWEEN INNOVATION AND POSITIVE COVERAGE DECISIONS

    Oct 1, 2018, 00:00

  • PIN96 - HIV/AIDS PROBLEM IN UKRAINE- CHALLENGE AND ACHIEVEMENT

    Oct 1, 2018, 00:00

  • PCP22 - KILL / REPLACE / REGULATE- MOLECULAR-LEVEL VIEW OF TREATING DISEASE, EMERGING SOLUTIONS AND IMPLICATIONS FOR THE FUTURE OF HEALTHCARE

    Oct 1, 2018, 00:00

  • PRM259 - THE CHALLENGES OF ESTIMATING MULTI-STATE MODEL TRANSITIONS IN RARE DISEASES- INFORMING AN ECONOMIC DECISION MODEL FOR DUCHENNE MUSCULAR DYSTROPHY

    Oct 1, 2018, 00:00

  • PMU71 - ESTIMATING THE CLINICAL AND ECONOMIC BURDEN OF ADDITIONAL HOSPITALISATION ASSOCIATED WITH HYPERKALAEMIA AND RAASI THERAPY MANAGEMENT- A MODELLING STUDY IN PATIENTS WITH CHRONIC KIDNEY DISEASE OR HEART FAILURE

    Oct 1, 2018, 00:00

  • PND16 - PHARMACEUTICAL TREATMENT OF MILD ALZHEIMER’S DISEASE IN GERMANY – RESULTS FROM A DELPHI PANEL

    Oct 1, 2018, 00:00

  • PND37 - COST OF MOTOR NEURONE DISEASE IN CYPRUS

    Oct 1, 2018, 00:00

  • PSY108 - COST-UTILITY ANALYSIS OF TOCILIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE TREATMENT OF GIANT CELL ARTERITIS IN ITALIAN PATIENTS

    Oct 1, 2018, 00:00

  • PCV134 - REAL-WORLD DATA SOURCES FOR HEART FAILURE RESEARCH- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PMD52 - YIELD AND COSTS OF POINT-OF-CARE SCREENING TEST VERSUS CASE FINDING TO DIAGNOSE CELIAC DISEASE IN PEDIATRIC PATIENTS

    Oct 1, 2018, 00:00

  • PHP362 - DO ALL RESEARCH GROUPS ALIGN ON THE VALUE OF AN INTERVENTION? CONCORDANCE OF COST-EFFECTIVENESS FINDINGS BETWEEN ICER REPORTS AND OTHER PUBLICATIONS

    Oct 1, 2018, 00:00

  • PHP252 - IS FACTOR ANALYSIS AS CREDIBLE AS OTHER TESTS OF DIFFERENCE AND ASSOCIATION FOR EVALUATING THE VALIDITY OF QUALITY OF LIFE MEASURES? ASSESSING THE CONVERGENT AND DISCRIMINANT VALIDITY OF THE WOMEN’S HEALTH QUESTIONNAIRE AGAINST THE ...

    Oct 1, 2018, 00:00

  • PSS28 - ECONOMIC EVALUATION OF LONG TERM CARE SERVICES- LESSONS LEARNED FROM A COST-EFFECTIVENESS ANALYSIS OF VISION REHABILITATION SERVICES IN ENGLAND

    Oct 1, 2018, 00:00

  • PSS14 - BUDGET IMPACT ANALYSIS OF CONBERCEPT AND RANIBIZUMAB IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION IN CHINA

    Oct 1, 2018, 00:00

  • PSY100 - COST-EFFECTIVENESS ANALYSIS OF SECOND LINE TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS

    Oct 1, 2018, 00:00

  • PCN262 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH LUNG CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PHP201 - DEVELOPMENT OF MEDICATION SAFETY STANDARDS IN SELECTED HOSPITALS IN IRAN

    Oct 1, 2018, 00:00

  • PRS64 - RIGHT TO BREATHE, RIGHT TO CHOOSE?

    Oct 1, 2018, 00:00

  • PRM73 - INCREASING NUMBERS OF REAL-WORLD/HEALTH ECONOMIC PUBLICATIONS IN CLINICAL RHEUMATOLOGY JOURNALS OVER THE PAST 15 YEARS

    Oct 1, 2018, 00:00

  • PHP223 - TRERAPEUTIC AREAS, A KEY FACTOR FOR HTA AND REIMBURSEMENT DECISIONS, TIMMING AND ACCESS

    Oct 1, 2018, 00:00

  • PSY112 - FACTOR UTILIZATION ANALYSIS OF EXTENDED DURATION AND STANDARD-ACTING RECOMBINANT FVIII TREATMENTS FOR SEVERE HEMOPHILIA A IN SWEDEN

    Oct 1, 2018, 00:00

  • PRM96 - COST-EFFECTIVENESS OF PRECISION ONCOLOGY DECISIONS- CHALLENGES IN METHODOLOGY

    Oct 1, 2018, 00:00

  • PCN263 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH PROSTATE CANCER IN SPAIN.

    Oct 1, 2018, 00:00

  • PCN81 - BUDGET IMPACT ANALYSIS OF CDK4/6 INHIBITORS FOR THE FIRST LINE THERAPHY OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PIN103 - A SYSTEMATIC REVIEW- COST-EFFECTIVENESS OF VACCINATION WITH NEW MENINGOCOCCAL SEROGROUP B VACCINES

    Oct 1, 2018, 00:00

  • PIN17 - BUDGET IMPACT ANALYSIS OF LIPOSOMAL AMPHOTERICIN B VERSUS AMPHOTERICIN B LIPID COMPLEX FOR THE TREATMENT OF INVASIVE FUNGAL INFECTIONS IN A TERTIARY HOSPITAL IN THE KINGDOM OF SAUDI ARABIA

    Oct 1, 2018, 00:00

  • PCN209 - ASSOCIATION BETWEEN AGE FACTORS AND STRATEGIES FOR PROMOTING PARTICIPATION IN GASTRIC AND COLORECTAL CANCER SCREENINGS

    Oct 1, 2018, 00:00

  • PCN315 - IMPACT OF PRO DATA ON IQWIG BENEFIT RATINGS IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PCN43 - A TARGETED REVIEW OF NICE SINGLE TECHNOLOGY APPRAISALS (STAS) IN UROTHELIAL CANCER SINCE THE INTRODUCTION OF THE NEW CANCER DRUGS FUND (CDF)

    Oct 1, 2018, 00:00

  • PCN303 - ASSESSING THE VALUE OF NOVEL IMMUNO-ONCOLOGY (I-O) THERAPIES- HOW CONSISTENT IS THE HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES' CONSIDERATION OF THE SURVIVAL BENEFIT IN THE ABSENCE OF LONG-TERM DATA?

    Oct 1, 2018, 00:00

  • PGI18 - USE OF PEG-COATED COLLAGEN HEMOSTATIC SELANT (HS)® IN PANCREATODUODENECTOMY (PD) SURGERY- INCIDENCE OF POSTOPERATIVE PANCREATIC FISTULA (POF) AND COST-BENEFIT ANALYSIS IN A RETROSPECTIVE STUDY

    Oct 1, 2018, 00:00

  • PIN78 - UPTAKE OF THE SEASONAL INFLUENZA VACCINATION AMONGST A COHORT OF PHARMACISTS IN IRELAND

    Oct 1, 2018, 00:00

  • PDB68 - COST-EFFECTIVENESS ANALYSIS OF EXENATIDE VERSUS GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PCN85 - SAVING HEALTHCARE AND SOCIETAL COSTS BY CHANGING THE ROUTE OF ADMINISTRATION OF ONCOLOGY DRUGS

    Oct 1, 2018, 00:00

  • PHP188 - EVOLVING INDICATIONS – AN ANALYSIS OF INDICATION FIELDS OVER TIME BASED ON GERMAN PRESCRIBING INFORMATION

    Oct 1, 2018, 00:00

  • PCN256 - INDICATION-SPECIFIC PRICING IN ONCOLOGY- HOW WILL U.S. PAYERS DETERMINE VALUE AMID THIS GROWING TREND?

    Oct 1, 2018, 00:00

  • PHP35 - AMNOG EARLY BENEFIT ASSESSMENT (EBA) AND MARKET PENETRATION OF NEW DRUGS FOR MELANOMA, MULTIPLE SCLEROSIS AND DIABETES MELLITUS IN GERMANY

    Oct 1, 2018, 00:00

  • PIN39 - IS THE UNIVERSAL POPULATION HEPATITIS C VIRUS SCREENING A COST-EFFECTIVE STRATEGY? A SYSTEMATIC REVIEW OF THE ECONOMIC EVIDENCE

    Oct 1, 2018, 00:00

  • PCN313 - HOSPITAL BASED HEALTH TECHNOLOGY ASSESSMENT PROGRAM AT KING HUSSEIN CANCER CENTER- ASSESSMENT OF FIVE YEARS EXPERIENCE

    Oct 1, 2018, 00:00

  • PND18 - PROGRESSION OF DISABILITY IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS- A RETROSPECTIVE COHORT STUDY USING DATA FROM THE MSBASE REGISTRY AND A CONTEXTUALISATION WITH AN EXISTING NATURAL HISTORY DATASET

    Oct 1, 2018, 00:00

  • PRM84 - LEVERAGING HOSPITAL-BASED EMR SYSTEMS FOR REAL-WORLD EVIDENCE GENERATION- OPPORTUNITIES AND CHALLENGES

    Oct 1, 2018, 00:00

  • PCN382 - QUALITY OF LIFE IN LONG-TERM CANCER SURVIVORS- IMPLICATIONS FOR FUTURE HEALTH TECHNOLOGY ASSESSMENTS IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PCN326 - COMPARATIVE ANALYSIS OF ESMO MAGNITUDE OF CLINICAL BENEFIT SCALE VALUES ASSIGNED TO NSCLC CANCER DRUGS, VERSUS REAL WORLD DATA ON PRESCRIBING ACTIVITY AND LEVELS OF SATISFACTION IN THE EU5

    Oct 1, 2018, 00:00

  • PHP40 - TRENDS IN THE INCLUSION OF NON-PHARMACEUTICAL HEALTH TECHNOLOGIES IN THE ISRAELI NATIONAL LIST OF HEALTH SERVICES

    Oct 1, 2018, 00:00

  • PND17 - PHARMACOEPIDEMIOLOGY OF LATERAL AMIOTROPHIC SCLEROSIS IN BELARUS

    Oct 1, 2018, 00:00

  • PIN59 - ESTIMATING THE COST-EFFECTIVENESS OF ISAVUCONAZOLE FOR THE TREATMENT OF PATIENTS WITH POSSIBLE INVASIVE ASPERGILLOSIS IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PND43 - CLINICAL CHARACTERISTICS AFFECTING DIRECT COSTS IN MULTIPLE SCLEROSIS

    Oct 1, 2018, 00:00

  • PCV49 - A REAL WORLD COST COMPARISON BETWEEN THOSE USING SALVIANOLATE INJECTION AND NOT AMONG CHINESE PATIENTS WITH CORONARY HEART DISEASE OR ANGINA PECTORIS- A RETROSPECTIVE DATABASE STUDY

    Oct 1, 2018, 00:00

  • PSY40 - ALL-CAUSE MORTALITY INCREASED WITH NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE IN US MEDICARE

    Oct 1, 2018, 00:00

  • PUK6 - A TARGETED REVIEW OF REAL-WORLD DATA SOURCES IN ANAEMIA OF CHRONIC KIDNEY DISEASE (CKD) IN EUROPE

    Oct 1, 2018, 00:00

  • PMH4 - PHARMACOECONOMICS OF ATYPICAL ANTIPSYCHOTICS INDUCED METABOLIC SYNDROME- A CRITICAL EVALUATION OF COST IMPLICATIONS AND HEALTH OUTCOMES

    Oct 1, 2018, 00:00

  • PMU55 - CONSEQUENCES ON ECONOMIC OUTCOMES OF GENERIC VERSUS BRAND-NAME DRUGS USED IN ROUTINE CLINICAL PRACTICE- THE CASE OF TREATING PERIPHERAL NEUROPATHIC PAIN OR GENERALIZED ANXIETY DISORDER WITH PREGABALIN

    Oct 1, 2018, 00:00

  • PHP104 - PRESCRIPTION DRUG USE AND INAPPROPRIATE PRESCRIBING AMONG PREGNANT WOMEN IN SOUTH KOREA

    Oct 1, 2018, 00:00

  • PHP9 - PATIENT INVOLVEMENT IN THE DRUG LIFE CYCLE ACCORDING TO STAKEHOLDERS- EXPLORING THE GAP BETWEEN THEORY AND PRACTICE

    Oct 1, 2018, 00:00

  • PCN280 - IMPACT OF SUBOPTIMAL CLINICAL EVIDENCE ON HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONS

    Oct 1, 2018, 00:00

  • PCV97 - HEARTH FAILURE IN VENETO REGION, ITALY- ANALYSIS OF THE THERAPEUTIC PATHWAYS AND CONSUMPTION OF HEALTH CARE RESOURCES

    Oct 1, 2018, 00:00

  • PIH41 - ANTIBIOTIC PRESCRIPTION PATTERNS OF PRIMARY CARE PHYSICIANS IN TREATING CHILDREN

    Oct 1, 2018, 00:00

  • PRM43 - A COST-UTILITY ANALYSIS OF THE ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM PLUS CATARACT SURGERY IN PATIENTS WITH MILD-TO-MODERATE OPEN-ANGLE GLAUCOMA IN FRANCE

    Oct 1, 2018, 00:00

  • PMU107 - DISCRETE CHOICE EXPERIMENTS IN HEALTH ECONOMICS- PAST, PRESENT AND FUTURE

    Oct 1, 2018, 00:00

  • PND109 - SICKLE-CELL DISEASE RELATED HOSPITALIZATIONS IN FRANCE - A REGIONAL DESCRIPTIVE ANALYSIS FROM THE FRENCH MEDICAL INFORMATION SYSTEM DATABASE IN 2016

    Oct 1, 2018, 00:00

  • PSS22 - ECONOMIC BURDEN OF DISEASE OF HIDRADENITIS SUPPURATIVA IN FINLAND- RESULTS FROM THE HI-FI STUDY

    Oct 1, 2018, 00:00

  • PND96 - FOUR-YEAR RESOURCE USE AND COSTS ASSOCIATED WITH ADMINISTRATION AND MONITORING OF DISEASE MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS

    Oct 1, 2018, 00:00

  • PCN284 - PRICING AND TIME-TO-MARKET FOR TYROSIN-KINASI INHIBITORS (TKIS) IN ITALY

    Oct 1, 2018, 00:00

  • PCN6 - SYSTEMATIC LITERATURE REVIEW OF EFFICACY SAFETY DATA FOR THE TREATMENT OF PREVIOUSLY UNTREATED, ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PND108 - INSOMNIA IN EVACUATION SHELTERS AFTER THE GREAT EAST JAPAN EARTHQUAKE

    Oct 1, 2018, 00:00

  • PSY141 - SUFENTANIL VERSUS FENTANYL FOR PAIN RELIEF IN LABOR WITH THE COMBINED SPINAL-EPIDURAL ANAESTHESIA - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

    Oct 1, 2018, 00:00

  • PCN312 - HOW HAS THE RELAUNCHED CANCER DRUGS FUND AFFECTED NICE’S APPROVAL OF NOVEL ONCOLOGY TECHNOLOGIES?

    Oct 1, 2018, 00:00

  • PDB112 - TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIES

    Oct 1, 2018, 00:00

  • PND100 - PRICING OF INNOVATIVE MEDICINES- DO INNOVATIVE SCHEMES OFFER A SOLUTION?

    Oct 1, 2018, 00:00

  • PDB126 - FACTORS INFLUENCING FOOD CHOICES OF PEOPLE WITH TYPE 2 DIABETES- A Q METHODOLOGY STUDY

    Oct 1, 2018, 00:00

  • PDB23 - THE CLINICAL GAP BETWEEN THE GUIDELINES AND PRACTICE OF STATINS PRESCRIBING AMONG DIABETIC PATIENTS

    Oct 1, 2018, 00:00

  • CP2 - USING REAL WORLD DATA TO EXTRAPOLATE EVIDENCE FROM RANDOMIZED CLINICAL TRIALS

    Oct 1, 2018, 00:00

  • PHP175 - EVOLUTION OF THE HEALTHCARE EXPENDITURES BY SERVICES IN HUNGARY BETWEEN 2010 AND 2015

    Oct 1, 2018, 00:00

  • PSY138 - COMPARATIVE EFFICACY AND SAFETY OF HYDROMORPHONE AND MORPHINE IN POST-CESAREAN SECTION ANALGESIA- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2018, 00:00

  • PMU72 - ESTIMATED COSTS OF PIVOTAL TRIALS FOR NOVEL THERAPEUTIC AGENTS APPROVED BY THE FDA, 2015-2016

    Oct 1, 2018, 00:00

  • PCP63 - DETERMINING THE OPTIMAL COST-EFFECTIVENESS CUTOFF FROM FIRST PRINCIPLES OF ECONOMICS

    Oct 1, 2018, 00:00

  • PCV103 - MANAGEMENT OF ATHEROGENIC DYSLIPIDEMIA IN REAL CLINICAL PRACTICE WITHIN THE SPANISH HEALTH SYSTEM ACCORDING TO CURRENT TREATMENT GUIDELINES- DESPEGA STUDY

    Oct 1, 2018, 00:00

  • PHP43 - EVIDENCE FOR HIGH RISK CLASS MEDICAL DEVICES VERSUS NEW DRUGS IN GERMANY- WHAT’S THE DIFFERENCE?

    Oct 1, 2018, 00:00

  • PRM154 - MODELING MIGRAINE DAY FREQUENCY BY RESPONDER STATUS- A RE-ANALYSIS OF DATA FROM ERENUMAB CLINICAL TRIALS

    Oct 1, 2018, 00:00

  • PRM142 - QUANTITATIVE BENEFIT-RISK MODELLING OF BIOSIMILARS- A CASE STUDY OF INFLIXIMAB IN CROHN’S DISEASE.

    Oct 1, 2018, 00:00

  • RM1 - SENSITIVITY ANALYSIS FOR NOT-AT-RANDOM MISSING DATA IN TRIAL-BASED COST-EFFECTIVENESS ANALYSIS USING MULTIPLE IMPUTATION

    Oct 1, 2018, 00:00

  • PHP162 - LICENCED ORPHAN MEDICINES EXPENDITURE IN TURKEY

    Oct 1, 2018, 00:00

  • PSY134 - HAS THE NICE HST PROCESS BEEN A SUCCESS? COMPARISON WITH OTHER EUROPEAN HTA BODIES

    Oct 1, 2018, 00:00

  • PCV12 - SHOULD KCENTRA BE ADDED FOR TREATMENT IN EMERGENCY WARFARIN REVERSAL?

    Oct 1, 2018, 00:00

  • PSY84 - IMPACT OF HIGH DISCONTINUATION RATES FOR SECUKINUMAB ON AVERAGE COSTS AND COST-EFFECTIVENESS RELATIVE TO OTHER BIOLOGICAL TREATMENTS OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN SWEDEN

    Oct 1, 2018, 00:00

  • PMU86 - VALUING HEALTH-STATE- AN EQ-5D-5L VALUE SET FOR ETHIOPIANS

    Oct 1, 2018, 00:00

  • PRM21 - MODELLING SURVIVAL OF PATIENTS WITH COMPLETELY RESECTED ADVANCED MELANOMA WITH ADJUVANT TREATMENT OF NIVOLUMAB VERSUS OBSERVATION

    Oct 1, 2018, 00:00

  • PSS6 - USING RANDOMISED CONTROLLED TRIAL (RCT) DATA AS EXTERNAL CONTROL TO OBTAIN COMPARATIVE EFFECTIVENESS IN A BAYESIAN NETWORK META-ANALYSIS MODEL

    Oct 1, 2018, 00:00

  • PHP159 - PUBLIC HEALTH AND ECONOMIC VALUE OF A NATIONWIDE PATIENT BLOOD MANAGEMENT PROGRAM

    Oct 1, 2018, 00:00

  • PSY169 - COMPARISON OF EU5 MARKET ACCESS DECISIONS FOR CROHN’S DISEASE BASED ON THE PRISMACCESS® DATABASE

    Oct 1, 2018, 00:00

  • PSS31 - COST PER RESPONDER OF SECUKINUMAB COMPARED TO OTHER BIOLOGICS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2018, 00:00

  • PMD157 - ASSESSMENT OF IN VITRO DIAGNOSTIC REIMBURSEMENT PRACTICES IN EUROPEAN COUNTRIES- IDENTIFIED HURDLES AND POSSIBLE SOLUTIONS.

    Oct 1, 2018, 00:00

  • PDB69 - COST-EFFECTIVENESS ANALYSIS OF ADDING PIOGLITAZONE TO INSULIN REGIMEN IN TYPE2 DIABETES IN IRAN

    Oct 1, 2018, 00:00

  • PSY217 - INCREMENTAL QUALITY-ADJUSTED SURVIVAL ANALYSIS WHEN NO HEAD TO HEAD DATA ARE AVAILABLE- A CASE STUDY OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ASM)

    Oct 1, 2018, 00:00

  • Test-Retest Reliability of EQ-5D-5L Valuation Techniques- The Composite Time Trade-Off and Discrete Choice Experiments

    Oct 1, 2018, 00:00

  • PMD177 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH DULAGLUTIDE AND SEMAGLUTIDE INJECTION DEVICES AMONG PATIENTS WITH TYPE 2 DIABETES IN ITALY

    Oct 1, 2018, 00:00

  • PMD72 - COST-EFFECTIVENESS ANALYSIS OF ADDING SPIROMETRY TO THE NATIONAL SCREENING PROGRAM FOR THE PURPOSE OF COPD CASE FINDING IN SOUTH KOREA

    Oct 1, 2018, 00:00

  • PHP309 - HTA CAPACITY BUILDING - OPPORTUNITIES AND CHALLENGES AS RESULT OF HTA INSTITUTIONS RESEARCH

    Oct 1, 2018, 00:00

  • PHP125 - COHORT TEMPORARY AUTHORISATION FOR USE IN FRANCE, FRENCH EXPERIENCE OF EARLY-ENTRY PROGRAM 2014-2018

    Oct 1, 2018, 00:00

  • PMU87 - HEALTH STATE UTILITY FOR COMORBID CONDITIONS- EVALUATING THE IMPACT OF DIFFERENT ESTIMATION METHODS

    Oct 1, 2018, 00:00

  • PIN94 - YELLOW FEVER IN COLOMBIA- FROM PUBLIC CALAMITY TO NEGLECTED DISEASE

    Oct 1, 2018, 00:00

  • PMU10 - USE OF A LIFETIME SIMULATION MODEL TO QUANTIFY THE IMPACT OF HYPERKALAEMIA ON PREDICTED AND QUALITY-ADJUSTED LIFE EXPECTANCY IN PATIENTS WITH HEART FAILURE OR CHRONIC KIDNEY DISEASE

    Oct 1, 2018, 00:00

  • PSS34 - COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT VERSUS RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA IN SPAIN

    Oct 1, 2018, 00:00

  • PSY22 - A REVIEW ON EPIDEMIOLOGY, RISK FACTORS AND TREATMENT PATTERNS IN MODERATE AND SEVERE PAINFUL DIABETIC NEUROPATHY AND POST-HERPETIC NEURALGIA

    Oct 1, 2018, 00:00

  • PSY71 - ECONOMIC BURDEN OF SPINAL MUSCULAR ATROPHY IN ITALY

    Oct 1, 2018, 00:00

  • PRS39 - COST-EFFECTIVENESS OF A NEW SINGLE INHALER TRIPLE THERAPY (SITT) VERSUS MULTIPLE INHALER TRIPLE THERAPIES (MITT) TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN CANADA

    Oct 1, 2018, 00:00

  • PHP253 - WAYS OF IMPROVING PHARMACEUTICAL ASSISTANCE IN UKRAINE THROUGH THE DEVELOPMENT OF PHARMACEUTIST PROTOCOLS

    Oct 1, 2018, 00:00

  • PCN290 - USE OF PCR AS A SURROGATE PRIMARY ENDPOINT IN DRUG PIVOTAL TRIALS IN NEOADJUVANT EARLY BREAST CANCER IN EU- A PERSPECTIVE FROM REGULATORS AND PAYERS

    Oct 1, 2018, 00:00

  • PHP242 - AN ANALYSIS OF THE TIMELINES THROUGHOUT THE REIMBURSEMENT PATHWAY FOR DRUGS IN IRELAND

    Oct 1, 2018, 00:00

  • PRM114 - SYNTHETIC SAMPLE GENERATION OF THE 4S STUDY PLACEBO POPULATION USING A STOCHASTIC RESAMPLING TECHNIQUE

    Oct 1, 2018, 00:00

  • PIN100 - ASSESSMENT OF MALAYSIAN PREGNANT WOMEN’S KNOWLEDGE, ATTITUDE AND BARRIERS TOWARDS INFLUENZA VACCINATION

    Oct 1, 2018, 00:00

  • PHP139 - G-BA CONDITIONAL APPROVALS IN THE AMNOG PROCEDURE- IMPACT ON HTA OUTCOMES AND PRICE

    Oct 1, 2018, 00:00

  • PSY4 - RESPONSE TO INDUCTION THERAPY, TREATMENT ADVERSE EVENTS AND HEALTHCARE RESOURCE USE IN INCIDENT ANCA-ASSOCIATED VASCULITIS (AAV) PATIENTS

    Oct 1, 2018, 00:00

  • PGI27 - THERAPEUTIC STRATEGIES UTILIZATION AND RESOURCES CONSUMPTION IN PATIENTS AFFECTED BY CROHN DISEASE (CD) OR ULCERATIVE COLITIS (UC) IN AN ITALIAN REAL-WORLD SETTING, VENETO REGION

    Oct 1, 2018, 00:00

  • PSY101 - LONG-TERM COST-EFFECTIVENESS OF EUROFIT VERSUS WAITING LIST

    Oct 1, 2018, 00:00

  • PRS10 - POPULATION HEALTH IMPACT OF OMALIZUMAB OVER 11 YEARS OF USE IN IRELAND IN MODERATE TO SEVERE ALLERGIC ASTHMA

    Oct 1, 2018, 00:00

  • PHP30 - THE CONTRIBUTION OF NEW PRODUCT ENTRY VS EXISTING PRODUCT INFLATION IN THE RISING COSTS OF PRESCRIPTION DRUGS IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PSS38 - LITERATURE REVIEW OF ECONOMIC EVALUATIONS IN RETINAL CONDITIONS

    Oct 1, 2018, 00:00

  • PCV39 - ASSESSMENT OF THE BUDGET IMPACT OF INTRAVENOUS FERRIC CARBOXYMALTOSE (FCM) FOR TREATING IRON DEFICIENCY ANEMIA IN CONGESTIVE HEART FAILURE PATIENTS IN GREECE

    Oct 1, 2018, 00:00

  • PMD84 - COST EFFECTIVENESS OF ENDOMETRIAL CANCER SCREENING AND PREVENTION - A SYSTEMATIC REVIEW OF ECONOMIC MODELS

    Oct 1, 2018, 00:00

  • PIH52 - AN INVESTIGATION INTO THE CONTENT VALIDITY AND FEASIBILITY OF THE EQ-5D-5L, SF-12, WEMWBS AND ONS-4 IN MEASURING THE QUALITY OF LIFE AND WELLBEING OF OLDER ADULTS.

    Oct 1, 2018, 00:00

  • PCN188 - ASSESSING THE ROBUSTNESS OF A COST-EFFECTIVENESS ANALYSIS OF LENVATINIB VERSUS SORAFENIB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA IN JAPAN

    Oct 1, 2018, 00:00

  • PCN79 - DECISION IMPACT OF A 21-GENE SIGNATURE IN EARLY BREAST CANCER- A NATURAL EXPERIMENT USING ROUTINE DATA

    Oct 1, 2018, 00:00

  • PIN50 - COST-EFFECTIVENESS OF GENDER-NEUTRAL NINE-VALENT HPV VACCINATION IN DENMARK

    Oct 1, 2018, 00:00

  • PSS16 - COST PER RESPONDER ANALYSIS OF CALCIPOTRIOL PLUS BETAMETHASONE DIPROPIONATE AEROSOL FOAM VERSUS NON-BIOLOGIC SYSTEMIC THERAPY IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS

    Oct 1, 2018, 00:00

  • PMD71 - PROCESS ANALYSIS AND SIMULATION MODELING OF A COMPUTED TOMOGRAPHY (CT) OF THE BRAIN FOCUSING ON THE EXPLORATION AND ASSESSMENT OF OPERATIONAL TIME AND COST SAVINGS

    Oct 1, 2018, 00:00

  • PRM68 - IMPUTATION METHODS FOR MISSING DATA IN COST-UTILITY ANALYSES ALONGSIDE RANDOMIZED CONTROLLED TRIALS- AGGREGATE OR NON-AGGREGATE?

    Oct 1, 2018, 00:00

  • PHP353 - ROMANIAN EXPERIENCE WITH MANAGED ENTRY AGREEMENTS FOR DRUGS

    Oct 1, 2018, 00:00

  • PRS30 - HOSPITAL MANAGEMENT OF ACUTE COPD EXACERBATION AND IMPACT ON HOSPITAL RE-ADMISSION IN FRANCE

    Oct 1, 2018, 00:00

  • PND122 - HEALTH STATE UTILITIES ASSOCIATED WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS), A RARE GENETIC DISORDER

    Oct 1, 2018, 00:00

  • PSS9 - DRUGS UTILISATION IN THE ITALIAN SETTING- THE CASE OF WAMD, DME AND RVO

    Oct 1, 2018, 00:00

  • QL2 - HEALTH UTILITY OF PATIENTS WITH TYPE 2 DIABETES AND VARIOUS SINGLE AND MULTIPLE COMPLICATIONS IN CHINA- A NATIONWIDE SURVEY

    Oct 1, 2018, 00:00

  • PIH19 - CAN THE PRINCIPLES AND GOOD PRACTICE OF BUDGET IMPACT ANALYSIS BE APPLIED IN SURGICAL CARE? - A MODEL FRAMEWORK FOR SURGICAL APPROACHES

    Oct 1, 2018, 00:00

  • PGI1 - ADVERSE EVENTS ASSOCIATED WITH THE TREATMENT OF INFLAMMATORY BOWEL DISEASE IN GERMANY

    Oct 1, 2018, 00:00

  • PCP19 - AN UPDATED NICE POSITION ON THE EQ-5D-5L VALUATION SET

    Oct 1, 2018, 00:00

  • MO4 - COMPARING MIXTURE CURE MODELS WITH STANDARD PARAMETRIC MODELS WITHIN THREE- AND FIVE-STATE PARTITION SURVIVAL FRAMEWORKS

    Oct 1, 2018, 00:00

  • PRS9 - SWITCHING FROM SUBCUTANEOUS TREPROSTINIL TO INHALED TREPROSTINIL IN PULMONARY ARTERIAL HYPERTENSION TREATMENT AND ECONOMIC IMPACT EVALUATION

    Oct 1, 2018, 00:00

  • PMU89 - EUROPEAN UNION 5 (EU5) NORMS FOR THE 3-LEVEL EQ-5D (EQ-5D-3L) QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PMU40 - LIVE BIRTH RATE (LBR), ONGOING PREGNANCY RATE (OPR) AND OVARIAN HYPERSTIMULATION SYNDROME (OHSS) RISK WITH ORIGINATOR VERSUS BIOSIMILAR RECOMBINANT FOLLITROPIN ALFA- A POOLED ANALYSIS OF CLINICAL TRIAL DATA

    Oct 1, 2018, 00:00

  • PHP10 - PATIENTS’ INVOLVEMENT IN THE DEVELOPMENT OF TARGET PRODUCT PROFILE, PRODUCT DEVELOPMENT PLAN AND THE DESIGN OF CLINICAL TRIALS

    Oct 1, 2018, 00:00

  • PHP189 - NATIONAL MY KANTA PAGES PATIENT PORTAL SERVICE- IMPLEMENTATION, USE AND USERS IN 2010-2017 IN FINLAND

    Oct 1, 2018, 00:00

  • PMU73 - EVIDENCE MAP OF ECONOMIC EVALUATIONS OF EXERCISE THERAPY PUBLISHED SINCE 2015

    Oct 1, 2018, 00:00

  • PHP245 - UNDERSTANDING THE IMPACT OF REAL WORLD EVIDENCE ON REIMBURSEMENT DECISIONS ACROSS EU5 COUNTRIES USING A WEB-BASED PORTAL TO ENGAGE PAYERS

    Oct 1, 2018, 00:00

  • PCV71 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF SYMPTOMATIC CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGAL

    Oct 1, 2018, 00:00

  • PND72 - COST-MINIMIZATION ANALYSIS OF TERIFLUNOMIDE AND DIMETHYL FUMARATE FOR TREATMENT OF RELAPSING-REMITTING FORMS OF MULTIPLE SCLEROSIS IN ITALY

    Oct 1, 2018, 00:00

  • PRS85 - VALIDATION OF AN EASY-TO-COMPLETE QUESTIONNAIRE FOR STUDYING PREDICTORS OF ADHERENCE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Oct 1, 2018, 00:00

  • PCN91 - PHARMACOECONOMIC EVALUATION OF ENZALUTAMIDE FOR THE TREATMENT OF POST-CHEMOTHERAPY PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN RUSSIA

    Oct 1, 2018, 00:00

  • PCN238 - TIME TO APPROVAL USING ACCELERATED MARKETING AUTHORIZATION PATHWAYS- A STUDY OF FIVE DEVELOPED COUNTRIES

    Oct 1, 2018, 00:00

  • PMH73 - THE BURDEN OF TREATMENT-RESISTANT DEPRESSION IN EUROPE FROM THE PATIENT PERSPECTIVE

    Oct 1, 2018, 00:00

  • PHP150 - GEOGRAPHICAL VARIABILITY IN THE UTILIZATION OF SERVICES AND PHARMACEUTICAL EXPENDITURE BY ADVANCED CHRONIC PATIENTS

    Oct 1, 2018, 00:00

  • PHP190 - THE PERCEPTION OF PROFESSIONALS OF HOW PEOPLE WITH DISABILITY ARE PERCEIVED BY THE PUBLIC

    Oct 1, 2018, 00:00

  • PRM121 - COMPARATIVE IMPACT OF TWO VARICELLA VACCINES ON VARICELLA EPIDEMIC DYNAMICS IN ITALY

    Oct 1, 2018, 00:00

  • PRM36 - COST-EFFECTIVENESS AND BUDGET IMPACT THRESHOLDS IN HEALTH TECHNOLOGY ASSESSMENT

    Oct 1, 2018, 00:00

  • PMU3 - SELF MEDICATION ATTITUDE, KNOWLEDGE, AND PERCEPTION

    Oct 1, 2018, 00:00

  • PCV62 - THE 1-YEAR PRODUCTIVITY LOSS AND INDIRECT COSTS AFTER ACUTE CARDIOVASCULAR EVENTS IN POLAND

    Oct 1, 2018, 00:00

  • PRS28 - COST OF ILLNESS DUE TO BACTERIAL PNEUMONIA IN THE ADULT POPULATION IN DOMINICAN REPUBLIC FROM A PUBLIC PERSPECTIVE DURING 2018

    Oct 1, 2018, 00:00

  • PND73 - THE IMPACT OF MODELLING SUBSEQUENT TREATMENT ON ESTIMATES OF COST-EFFECTIVENESS- AN ANALYSIS OF DISEASE-MODIFYING TREATMENTS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PCV27 - HEART FAILURE SIGNS AND SYMPTOMS AND REFERRALS TO HOSPITAL ARE REDUCED FOLLOWING SACUBITRIL/VALSARTAN TREATMENT IN THE PRIMARY CARE AND CARDIOLOGIST SETTING IN GERMANY

    Oct 1, 2018, 00:00

  • PCN9 - BRAIN TUMOR RESECTION SURGERY IN PEDIATRIC PATIENTS; RETROSPECTIVE EPIDEMIOLOGICAL STUDY USING JAPANESE ADMINISTRATIVE DATABASE

    Oct 1, 2018, 00:00

  • PHP282 - NEW AIFA INNOVATION ALGORITHM- IS IT REALLY A STEP FORWARD IN ALIGNING AIFA’S DECISION WITH EUROPEAN HTAS?

    Oct 1, 2018, 00:00

  • PRM51 - A NEW CONCEPTUAL MODEL OF THE COST-EFFECTIVENESS THRESHOLD

    Oct 1, 2018, 00:00

  • PCN365 - AN ASSESSMENT OF PATIENT REPORTED OUTCOME (PRO) CLINICAL TRIAL DATA REPORTING, SPECIFIC TO CHOLANGIOCARCINOMA (CCA)

    Oct 1, 2018, 00:00

  • PCN177 - COST-EFFECTIVENESS OF TISAGENLECLEUCEL FOR ADULTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA - A CANADIAN SOCIETAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PHP134 - THE CHALLENGES OF PHARMACEUTICAL INDUSTRY IN IRAN; THEIR ROOTS, RANKS, AND RESOLUTIONS

    Oct 1, 2018, 00:00

  • PMU41 - PAST, CURRENT AND EXPECTED NEED FOR HOME ARTIFICIAL NUTRITION IN PIEDMONT- RESOURCES NEEDED TO MAINTAIN A RECOGNIZED HIGH QUALITY LEVEL

    Oct 1, 2018, 00:00

  • PRM57 - ASSESSMENTS OF ECONOMIC VALUE USING FIVE DIFFERENT ONCOLOGY VALUE FRAMEWORKS (ASCO, ESMO, NCCN, MSKCC, ICER)

    Oct 1, 2018, 00:00

  • PRM151 - ASSESSING THE EXTERNAL VALIDITY OF MAPPING ALGORITHMS TO ESTIMATE CHU9D UTILITIES FROM THE PEDSQLTM IN DISPARATE SUB-GROUPS

    Oct 1, 2018, 00:00

  • Unique Review Criteria and Patient and Stakeholder Reviewers- Analysis of PCORI’s Approach to Research Funding

    Oct 1, 2018, 00:00

  • PMS78 - CHANGES IN THE PRICES OF INCUMBENT TNF-ALPHA INHIBITORS FOLLOWING THE MARKET ENTRY OF COMPETITORS

    Oct 1, 2018, 00:00

  • PMD120 - HEALTHCARE OUTCOMES OF ONE-STEP DIAGNOSIS IN PATIENTS WITH CHRONIC HEPATITIS C

    Oct 1, 2018, 00:00

  • PIN60 - ECONOMIC EVALUATION OF BCG VACCINATION - A SYSTEMATIC REVIEW AND QUALITY ASSESSMENT

    Oct 1, 2018, 00:00

  • PDB64 - SHORT-TERM COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC IN JAPANESE PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PMH43 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED CENTRAL AND EASTERN EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • AC4 - RETROSPECTIVE ANALYSIS OF INAPPROPRIATE MEDICATION PRESCRIPTION INDICATORS IN ELDERLY POPULATION IN ITALY

    Oct 1, 2018, 00:00

  • PND30 - ECONOMIC IMPACT OF AUTISM SCREENING IN EUROPE

    Oct 1, 2018, 00:00

  • PHP110 - SUBSTANTIAL HEALTH GAINS FROM HEATH-SYSTEM-WIDE PATIENT BLOOD MANAGEMENT IMPLEMENTATION- ANALYTICS FOR EUROPE

    Oct 1, 2018, 00:00

  • PRS104 - USING OF "THE FOOD HYPERSENSITIVITY FAMILY IMPACT” (FLIP) QUESTIONNAIRE FOR ASSESSMENT OF QUALITY OF LIFE OF FOOD-ALLERGIC CHILD'S FAMILY MEMBERS.

    Oct 1, 2018, 00:00

  • PMD156 - NEXT GENERATION SEQUENCING- BENEFIT ANALYSIS TO SUPPORT A STRATEGIC ADOPTION MODEL IN THE ITALIAN NHS

    Oct 1, 2018, 00:00

  • PIN88 - HOSPITALIZATION RATES AMONG EMERGENCY ROOM-DIAGNOSED HIV+ PATIENTS IN THE US AND EU5

    Oct 1, 2018, 00:00

  • PRM233 - THE USE OF THE TWO-STAGE METHOD IN ADJUSTING FOR TREATMENT CROSSOVER. A SIMULATION STUDY.

    Oct 1, 2018, 00:00

  • PRM28 - PERFORMANCE OF THE EARLY WARNING SYSTEM VITAL TO PREDICT UNANTICIPATED HIGHER-LEVEL OF CARE ADMISSION AND IN-HOSPITAL DEATH OF WARD PATIENTS

    Oct 1, 2018, 00:00

  • PMD92 - ECONOMIC EVALUATION OF INSERTABLE CARDIAC MONITORS TO DETECT ATRIAL FIBRILLATION AND SUBSEQUENTLY MODERATE STROKE RISK IN A HIGH-RISK POPULATION IN THE UK

    Oct 1, 2018, 00:00

  • PRM221 - NETWORK META-ANALYSIS IN THE PRESENCE OF NON-PROPORTIONALITY- A REVIEW OF NICE SUBMISSIONS

    Oct 1, 2018, 00:00

  • PSS51 - ANALYSIS OF TOPICAL PREPARATIONS FOR TREATMENT OF ONYCHOMYCOSIS IN UKRAINE

    Oct 1, 2018, 00:00

  • PSS4 - IMPORTANCE OF PROPERLY ADJUSTING FOR HETEROGENEITY AMONG NETWORK META-ANALYSES CONSIDERING OUTCOMES WITH MULTIPLE PRE-DEFINED LEVELS- AN ILLUSTRATIVE EXAMPLE IN PSORIASIS

    Oct 1, 2018, 00:00

  • PIN21 - ECONOMIC BURDEN OF CERVICAL SCREENING AND TREATMENT OF HPV-RELATED CERVICAL LESIONS AND CANCERS IN EUROPE

    Oct 1, 2018, 00:00

  • PHP31 - IMPACT OF EUROPEAN MEDICINES AGENCY (EMA) CLINICAL TRIAL TRANSPARENCY POLICIES ON HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS IN GERMANY

    Oct 1, 2018, 00:00

  • PHP144 - IMPACT OF A CREATIVE QUALITY IMPROVEMENT STRATEGY TO REDUCE PATIENT WAIT TIMES BETWEEN PRIMARY AND SPECIALITY CARE IN A TERTIARY, UNIVERSITY PUBLIC HOSPITAL IN PORTUGAL

    Oct 1, 2018, 00:00

  • PHP230 - EU5 MARKET ACCESS FOR MEDICINES APPROVED UNDER EXCEPTIONAL CIRCUMSTANCES

    Oct 1, 2018, 00:00

  • PCP32 - INTRODUCTION OF TRIAL-BASED ECONOMIC EVALUATIONS IN UKRAINE- ANALYSIS OF PERSPECTIVES AND BARRIES

    Oct 1, 2018, 00:00

  • PIN36 - PUBLIC HEALTH AND ECONOMIC IMPACT OF GENDER-NEUTRAL HUMAN PAPILLOMAVIRUS (HPV) VACCINATION WITH THE NONAVALENT HPV VACCINE IN BELGIUM (WALLONIA REGION) USING A TRANSMISSION DYNAMIC MODEL

    Oct 1, 2018, 00:00

  • PRM152 - A GENERIC BAYESIAN DES MODEL FOR MULTI-STATE DISEASE PROGRESSION

    Oct 1, 2018, 00:00

  • PCN383 - ESTIMATING THE HEALTH IMPACT OF INCREASING BREAST AND CERVICAL CANCER SCREENING IN THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM AMONG LOW-INCOME WOMEN IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PSY115 - A COST-EFFECTIVENESS ANALYSIS OF RAASI – ENABLING PATIROMER FOR THE TREATMENT OF HYPERKALEMIA IN AUSTRIA

    Oct 1, 2018, 00:00

  • PHP52 - ACCESSIBILITY AND ACCESS TO ORPHAN DRUGS IN PORTUGAL- HOW FAR ARE WE?

    Oct 1, 2018, 00:00

  • PDB103 - FINANCIAL ACCESS TO HEALTH CARE USE IN DIABETICS WITH HIGH-DEDUCTIBLE HEALTH PLAN (HDHP)

    Oct 1, 2018, 00:00

  • PCN146 - INOTUZUMAB OZOGAMICIN IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE LYMPHOCYTIC LEUKEMIA (ALL)- ESTABLISHING A VALUE-BASED COST – PRELIMINARY RESULTS

    Oct 1, 2018, 00:00

  • PND155 - REDUCED RELAPSE RATES AND IMPROVED QUALITY OF LIFE FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS TREATED WITH NATALIZUMAB VS INJECTABLE THERAPIES

    Oct 1, 2018, 00:00

  • PSY102 - MUCOPOLYSACCHARIDOSIS DRUG COVERAGE IN RUSSIA- EXPEDIENCY OF DRUG PROCUREMENT CENTRALIZATION

    Oct 1, 2018, 00:00

  • PCN48 - REAL-WORLD TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER- RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANY

    Oct 1, 2018, 00:00

  • PHP208 - PHYSICIANS’ IMPROVEMENT SUGGESTIONS FOR ENTERAL NUTRTION CARE IN CHINA- A CROSS-SECTIONAL SURVEY

    Oct 1, 2018, 00:00

  • PIH49 - KNOWLEDGE ABOUT MENSTRUAL HYGIENE – TOXIC SHOCK SYNDROME

    Oct 1, 2018, 00:00

  • PND146 - MS PATIENTS’ PERCEPTION OF THE EFFECTS OF PR-FAMPRIDINE ON WALKING DISORDERS AND DAILY LIFE- RESULTS FROM AN OBSERVATIONAL STUDY CONDUCTED VIA AN ONLINE PATIENT COMMUNITY

    Oct 1, 2018, 00:00

  • PDB77 - LONG-TERM COST-EFFECTIVENESS ANALYSIS OF IDEGLIRA VERSUS IGLARLIXI FOR THE TREATMENT OF PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN IN THE ITALIAN SETTING

    Oct 1, 2018, 00:00

  • PMH74 - QUALITY OF LIFE ACCORDING TO TEMPORAL ILLICIT OPIOID USE AND RESPONDER RATE IN ADULTS RECEIVING BUPRENORPHINE DEPOT INJECTIONS (CAM2038) TO TREAT OPIOID USE DISORDER IN A 48-WEEK OPEN LABEL STUDY

    Oct 1, 2018, 00:00

  • PCV63 - ECONOMIC BURDEN ASSOCIATED WITH SECONDARY CARDIOVASCULAR (CV) EVENTS – A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PUK14 - LOW-DOSE ORAL DESMOPRESSIN LYOPHILISATE IS A COST-EFFECTIVE TREATMENT OPTION FOR PATIENTS EXPERIENCING AT LEAST TWO NOCTURNAL MICTURITIONS

    Oct 1, 2018, 00:00

  • PIN70 - INVESTIGATING THE SECONDARY CARE SYSTEM BURDEN OF INFLUENZA HOSPITALISATION IN CLINICAL RISK GROUPS USING THE HES DATABASE

    Oct 1, 2018, 00:00

  • PHP51 - UTILIZTION OF MONOCLONAL ANTIBODY IN CHINA- A STUDY FROM NATOINAL MARKET ACCESS VIEW

    Oct 1, 2018, 00:00

  • PMH28 - ECONOMIC IMPACT OF EARLY TREATMENT ON LIFETIME COSTS OF ALZHIEMER’S DISEASE IN CZECHIA

    Oct 1, 2018, 00:00

  • PRS33 - THE CLINICAL AND ECONOMIC BURDEN OF IDIOPATHIC PULMONARY FIBROSIS IN ALGERIA

    Oct 1, 2018, 00:00

  • PND74 - COST UTILITY MODEL OF BRIVARACETAM IN THE ADJUNCTIVE TREATMENT FOR PARTIAL-ONSET EPILEPTIC SEIZURES IN SPAIN

    Oct 1, 2018, 00:00

  • PND127 - QUALITY OF LIFE IN PAEDIATRIC MULTIPLE SCLEROSIS- SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN133 - THE SOCIETAL IMPACT OF OBINUTUZUMAB IN THE FIRST LINE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA IN GERMANY

    Oct 1, 2018, 00:00

  • PIN45 - COST-EFFECTIVENESS OF CEFTAZIDIME/AVIBACTAM FOR THE TREATMENT OF INFECTIONS DUE TO AEROBIC GRAM-NEGATIVE ORGANISMS IN PATIENTS WITH LIMITED TREATMENT OPTIONS

    Oct 1, 2018, 00:00

  • PGI23 - COST-EFFECTIVENESS ANALYSIS OF PARENTERAL METHOTREXATE FOR THE TREATMENT OF CROHN’S DISEASE IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PCN119 - SECONDARY CARE RESOURCE UTILIZATION AND COST OF CARE AMONG FINNISH NON-SMALL CELL LUNG CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PRM71 - ESTIMATION OF THE NUMBER OF PNEUMONIA PATIENTS IN JAPAN USING PUBLIC REAL-WORLD DATA

    Oct 1, 2018, 00:00

  • PRM231 - REPORT OF NETWORK META-ANALYSIS GEOMETRY- A SYSTEMATIC REVIEW AND METRICS RECOMMENDATION

    Oct 1, 2018, 00:00

  • PMD107 - COST-EFFECTIVENESS ANALYSIS OF NEXT GENERATION RENAL DENERVATION THERAPY DEVICES- THRESHOLD ANALYSIS AND PROJECTIONS OF THE SPYRAL HTN-ON MED TRIAL FOR GERMANY

    Oct 1, 2018, 00:00

  • PIN129 - ADAPTING INFLUENZA PATIENT-REPORTED OUTCOMES (PRO) MEASURES TO MONITOR RESPIRATORY SYNCYTIAL VIRUS (RSV) SYMPTOM SEVERITY IN ADULTS- QUALITATIVE EVIDENCE OF KEY CONCEPTS AND CONTENT VALIDITY

    Oct 1, 2018, 00:00

  • PMU6 - THE RELATIONSHIP BETWEEN INTEGRATION DISABILITY POLICIES AND INTENTION OF EARLY RETIREMENT WITHIN A CONTEXT OF MULTIMORBIDITY- RESULTS FROM THE SURVEY OF HEALTH, AGEING AND RETIREMENT IN EUROPE (SHARE)

    Oct 1, 2018, 00:00

  • PMD1 - POST-ND-YAG LASER COMPLICATIONS IN CATARACT PATIENTS TREATED FOR POSTERIOR CAPSULAR OPACIFICATION- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PND157 - ENHANCEMENT FOR STROKE PATIENT’S OUTCOMES. EGYPT MODEL

    Oct 1, 2018, 00:00

  • PMD121 - EXPLORING THE DAILY CLINICAL PRACTICE IN MYOCARDIAL INFARCTION (MI) CARE IN EUROPE- SURVEY OF DIAGNOSTIC AND TREATMENT STRATEGIES FOR THEORETICAL PATIENTS

    Oct 1, 2018, 00:00

  • PMU44 - TOP 10 MOST COSTLY DISEASES IN CHINA- A BIG-DATA DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PRM53 - THE USE OF PROXY MARKERS TO DEFINE DISEASE STAGE IN PATIENTS WITH MALIGNANT MELANOMA- AN OBSERVATIONAL STUDY USING THE HOSPITAL EPISODE STATISTICS (HES) DATABASE IN ENGLAND

    Oct 1, 2018, 00:00

  • PHP198 - EVALUATION OF THE SWEDISH EARLY AWARENESS AND ALERT SYSTEM

    Oct 1, 2018, 00:00

  • PRM225 - EVALUATING PREVIOUS MIGRAINE HEADACHE FREQUENCY STATISTICAL MODELLING APPROACHES USING AN INDEPENDENT DATASET FROM THE EVOLVE STUDIES IN EPISODIC MIGRAINE

    Oct 1, 2018, 00:00

  • PHP86 - IMPORTANCE OF CRITERIA FOR DRUG REIMBURSEMENT DECISION-MAKING FOR NON-LIFE-THREATENING DISEASES

    Oct 1, 2018, 00:00

  • PCN239 - NICE AND THE CANCER DRUGS FUND- APPRAISING TREATMENTS FOR RARER CANCERS IN ENGLAND

    Oct 1, 2018, 00:00

  • PSS42 - SECUKINUMAB SIGNIFICANTLY REDUCES PSORIASIS-RELATED WORK IMPAIRMENT AND INDIRECT COSTS COMPARED TO USTEKINUMAB AND ETANERCEPT IN MOROCCO

    Oct 1, 2018, 00:00

  • PCN296 - BIG DATA ANALYSIS OF CANCER TREATMENT IN GERMANY - MAPPING OF TREATMENT LANDSCAPE BASED ON A GERMAN STATUTORY HEALTH INSURANCE (SHI) CLAIMS DATA ANALYSIS

    Oct 1, 2018, 00:00

  • PSS61 - PROCESS UTILITIES FOR TOPICAL TREATMENT IN ATOPIC DERMATITIS

    Oct 1, 2018, 00:00

  • PND91 - HOW ADVANCED THERAPY TREATMENT CENTERS IN THE UK CAN IMPROVE MARKET ACCESS FOR SPECIALISED TECHNOLOGIES

    Oct 1, 2018, 00:00

  • PND153 - ANALYSIS OF RESPONSES TO SF-36V2 ITEMS FOR PATIENTS WITH HATTR AMYLOIDOSIS- RESULTS FROM A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PIH9 - BACTERIOLOGICAL PROFILE AND ANTIBIOGRAM OF NEONATAL SEPSIS IN THE NEONATAL INTENSIVE CARE UNIT OF AN EGYPTIAN HOSPITAL

    Oct 1, 2018, 00:00

  • PMD147 - CHARACTERIZING HEALTH CARE RESOURCE UTILIZATION AND COSTS FOLLOWING INTRAMEDULLARY FIXATION FOR PERTROCHANTERIC HIP FRACTURE IN A MEDICARE POPULATION

    Oct 1, 2018, 00:00

  • PMD148 - THE BUDGET IMPACT OF GLOBAL TELEMEDICINE SOLUTION IN FRANCE

    Oct 1, 2018, 00:00

  • PHP272 - QUANTITATIVE ASSESSMENT OF TECHNICAL ERRORS FOUND IN ECONOMIC MODELS SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Oct 1, 2018, 00:00

  • PMS67 - DEVELOPMENT OF A PATIENT DECISION AID (PDA) FOR PATIENTS WITH RHEUMATOID ARTHRITIS THAT REDUCES DECISIONAL CONFLICT AND IMPROVES READINESS FOR TREATMENT DECISION MAKING

    Oct 1, 2018, 00:00

  • PGI40 - THE ROLE OF PERFORMANCE-BASED RISK-SHARING AGREEMENTS IN MINIMISING PAYER UNCERTAINTY WHEN STANDARD OF CARE IS NOT CLEARLY DEFINED; THE EXAMPLE OF CROHN’S DISEASE RELATED COMPLEX PERIANAL FISTULAS

    Oct 1, 2018, 00:00

  • PMS15 - CHILDHOOD OBESITY IS ASSOCIATED WITH BACK PAIN- A COHORT STUDY OF 466,997 INDIVIDUALS

    Oct 1, 2018, 00:00

  • PND115 - A COMPARISON OF FDA AND EMA GUIDANCE ON MEDICINES FOR THE TREATMENT OF ALZHEIMER’S DISEASE

    Oct 1, 2018, 00:00

  • PND97 - DEVELOPING STROKE SYSTEM CARE FOR LOW MIDDLE INCOME COUNTRIES. EGYPT MODEL

    Oct 1, 2018, 00:00

  • PCV64 - THE DIRECT RESOURCE USE AND MEDICAL COSTS OF HEART FAILURE IN NOVA SCOTIA, CANADA

    Oct 1, 2018, 00:00

  • PRM135 - DICE FOR NICE? LESSONS FROM A SINGLE TECHNOLOGY APPRAISAL

    Oct 1, 2018, 00:00

  • PIN5 - 10 YEARS OF HUMAN PAPILLOMAVIRUS SYSTEMATIC VACCINATION IN SPAIN- FORECASTING HEALTH OUTCOMES CONSIDERING AS04-HPV16/18 VACCINE EFFECTIVENESS DATA

    Oct 1, 2018, 00:00

  • PSS47 - A COHORT STUDY TO INVESTIGATE THE FACTORS ASSOCIATED WITH THE INTENTION TO USE ILLEGAL DRUG AMONG SAUDI STUDENTS

    Oct 1, 2018, 00:00

  • PHP60 - PAYER ARCHETYPING – EXPANDING HORIZONS

    Oct 1, 2018, 00:00

  • PMU77 - ANALYSIS OF DECISIONS OF PATIENTS NOT TO PURCHASE PRESCRIPTION MEDICINES. RESULTS OF THE CROSS-SECTIONAL PHARMACY-BASED SURVEY CONDUCTED IN POLAND

    Oct 1, 2018, 00:00

  • PCV84 - COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION SPANISH PATIENTS

    Oct 1, 2018, 00:00

  • PSS41 - SECUKINUMAB SIGNIFICANTLY REDUCES PSORIASIS-RELATED WORK IMPAIRMENT AND INDIRECT COSTS COMPARED TO USTEKINUMAB AND ETANERCEPT IN TUNISIA

    Oct 1, 2018, 00:00

  • PHP247 - RISK-BASED CONTRACTING AND U.S. INSURERS- PAYER WILLINGNESS TO PARTICIPATE AND PREFERRED METRICS IN CHRONIC INDICATIONS

    Oct 1, 2018, 00:00

  • PND94 - A RETROSPECTIVE DATABASE ANALYSIS OF HEALTHCARE RESOURCE UTILIZATION AND ASSOCIATED COSTS AMONG PATIENT TREATED WITH RUFINAMIDE IN UK

    Oct 1, 2018, 00:00

  • PMS55 - THE EFFECTS OF MORTALITY ASSUMPTIONS ON THE COST EFFECTIVENESS OF A NEW GOUT TREATMENT

    Oct 1, 2018, 00:00

  • PMH53 - THE TREATMENT OF SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDERS- ANALYSIS OF REAL WORLD EVIDENCE FROM THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PHP66 - CURRENT OPPORTUNITIES AND CHALLENGES IN MARKET ACCESS OF E-HEALTH SOLUTIONS

    Oct 1, 2018, 00:00

  • PHP45 - AN INITIAL ANALYSIS OF THE COST-BASED PRICING REVISIONS IN JAPAN

    Oct 1, 2018, 00:00

  • PCP51 - OBSERVATIONAL STUDIES COLLECTING PATIENT PREFERENCES AND EXPERIENCES- REGULATORY DIFFERENCES ACROSS COUNTRIES IN EUROPE

    Oct 1, 2018, 00:00

  • PIN35 - COST-EFFECTIVENESS OF BEZLOTOXUMAB FOR THE PREVENTION OF RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION IN PORTUGAL

    Oct 1, 2018, 00:00

  • PMH66 - REAL WORLD ANALYSIS EVALUATING FACTORS ASSOCIATED WITH TREAMENT CHANGE IN PARKINSON'S DISEASE PSYCHOSIS

    Oct 1, 2018, 00:00

  • PRM146 - CURRENT AND FUTURE TRENDS IN METHODOLOGIES OF SURVIVAL CURVE EXTRAPOLATION IN ONCOLOGY ACCEPTED BY HTA AUTHORITIES.

    Oct 1, 2018, 00:00

  • PIN31 - ECONOMIC EVALUATION OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE ON CMV-SEROPOSITIVE RECEPTORS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT IN THE PORTUGUESE SETTING

    Oct 1, 2018, 00:00

  • PSY145 - IMPACT OF BIOSIMILAR ENTRY ON PRICE AND UPTAKE OF BRANDED BIOLOGICS FOR THE TREATMENT OF AUTOIMMUNE DISEASES

    Oct 1, 2018, 00:00

  • PRS106 - THE ASSESSMENT THE QUALITY OF LIFE IN CHILDREN WITH SEVERE PERSISTENT UNCONTROLLED ASTHMA, RECEIVING OMALIZUMAB, BY THE HEALTH UTILITIES INDEX AND STANDARDISED PAEDIATRIC ASTHMA QUALITY OF LIFE QUESTIONNAIRE(ACCORDING TO THE PEDIAT ...

    Oct 1, 2018, 00:00

  • PHP123 - REGIONAL DISPARITIES IN THE DISTRIBUTION OF HEALTH CARE FACILITIES- VISUALIZATION OF REGIONAL MEDICAL CARE SUPPORT HOSPITALS

    Oct 1, 2018, 00:00

  • PSY26 - OPIOID PRESCRIBING IN A SOUTH AFRICAN MEDICAL INSURANCE SCHEME SETTING

    Oct 1, 2018, 00:00

  • PCN343 - KNOWLEDGE ABOUT HUMAN PAPILLOMAVIRUS (HPV) IN PARENTS OF TEENAGE BOYS IN HUNGARY

    Oct 1, 2018, 00:00

  • PCN375 - ASSESSING NUTRITIONAL STATUS AMONG PATIENTS WITH LUNG CANCER

    Oct 1, 2018, 00:00

  • PSY210 - HEALTH-RELATED QUALITY OF LIFE AFTER BARIATRIC SURGERY – A PROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PCN11 - GLOBAL LONGITUDINAL ASSESSMENT OF TREATMENT OUTCOMES IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (GLANCE-HN) STUDY

    Oct 1, 2018, 00:00

  • PRS40 - COST-EFFECTIVENESS OF THE SQ® GRASS SUBLINGUAL IMMUNOTHERAPY (SLIT) TABLET IN A PAEDIATRIC POPULATION

    Oct 1, 2018, 00:00

  • PSY51 - CLINICAL AND ECONOMIC ASPECTS OF ENZYME REPLACEMENT THERAPY IN RUSSIAN PATIENTS WITH GAUCHER DISEASE TYPE 1

    Oct 1, 2018, 00:00

  • PGI5 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION AFTER COLORECTAL SURGERY

    Oct 1, 2018, 00:00

  • PCV159 - THE IMPACT OF SUBSEQUENT CARDIOVASCULAR (CV) EVENTS ON HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH A PRIOR MYOCARDIAL INFARCTION (MI) - A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PRS65 - ASSESSING THE IMPACT OF CONCURRENT PRESCRIPTION OPIOID USE ON ADHERENCE TO MAINTENANCE MEDICATIONS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- A RETROSPECTIVE CLAIMS ANALYSIS

    Oct 1, 2018, 00:00

  • PDB16 - COMPARE RENAL FUNCTIONAL PRSERVATION OUTCOME OF SGLT2 INHIBITOR VS DPP4 INHIBITOR IN PATIENTS WITH TYPE 2 DIABETES- A RETROSPECTIVE COHORT STUDY OF JAPANESE COMMERCIAL DATABASE WITH ADVANCED ANALYTICS APPROACH

    Oct 1, 2018, 00:00

  • PIN84 - THE STUDY OF THE CONSUMPTION OF ANTIVIRAL DRUGS USED FOR PHARMACOTHERAPY IN PATIENTS WITH ACUTE RESPIRATORY VIRAL INFECTIONS IN UKRAINE

    Oct 1, 2018, 00:00

  • PUK26 - IMPACT OF EMERGING HIF-PH INHIBITORS ON RENAL ANEMIA TREATMENT

    Oct 1, 2018, 00:00

  • PSY206 - COMPLEMENTARY AND ALTERNATIVE MEDICINE FOR PAIN- USAGE, OUTCOMES AND COST

    Oct 1, 2018, 00:00

  • PSY7 - IMPACT OF OBESITY ON GLYCATED HEMOGLOBIN CONTROL AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PRM242 - USING NON-RANDOMISED EVIDENCE OR CLINICAL ASSUMPTIONS TO MAKE CONNECTIONS IN NETWORK META-ANALYSIS - A CASE STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

    Oct 1, 2018, 00:00

  • PMD187 - COMPARISON OF PERIPHERAL INTRAVENOUS CANNULA DRESSINGS

    Oct 1, 2018, 00:00

  • HT5 - FINDINGS FROM THE FIRST FIVE YEARS OF THE UK NICE HST PROGRAM

    Oct 1, 2018, 00:00

  • PHP73 - FACTORS INFLUENCING THE DURATION OF MEDICINE PRICE NEGOCIATION IN FRANCE

    Oct 1, 2018, 00:00

  • PCP68 - MEDICAL ACCESS STRATEGY TO IMPROVE ACCESS TO INNOVATIVE AND EXPENSIVE THERAPY IN FRANCE

    Oct 1, 2018, 00:00

  • PRM159 - AN EVALUATION OF SURVIVAL CURVE EXTRAPOLATION TECHNIQUES USING LONG-TERM OBSERVATIONAL CANCER DATA

    Oct 1, 2018, 00:00

  • PMD127 - FIRST DO NO HARM? EXPLORING THE INTERPRETATION OF NICE DIAGNOSTIC ASSESSMENTS WITH COST SAVINGS AND QALY LOSS

    Oct 1, 2018, 00:00

  • PCN269 - HEALTHCARE RESOURCE USE (HRU) ASSOCIATED WITH TREATMENT IN ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) RELAPSED OR REFRACTORY (R/R) B-CELL PRECURSOR (BCP) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN EU-4 COUNTRIES

    Oct 1, 2018, 00:00

  • PRM189 - SUBJECTIVE MEASURE MAY BE MORE SENSITIVE IN IDENTIFYING PROGNOSTIC FACTORS OF FUNCTIONAL OUTCOME AMONG OLDER ADULTS WITH SURGICALLY-TREATED HIP FRACTURE – FINDINGS FROM A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PCN272 - ANALYSIS OF PHARMACY CLAIMS FOR HIGH COST DRUGS- LENALIDOMIDE UTILISATION AND EXPENDITURE IN IRELAND

    Oct 1, 2018, 00:00

  • PHP71 - HOW A NEW INNOVATION ASSESSMENT TOOL RELATES TO RECENT DRUG LAUNCHES FOR SPANISH NATIONAL ACCESS

    Oct 1, 2018, 00:00

  • PDB97 - TYPE 2 DIABETES- OUTCOME OF DRUG TREATMENT IN PATIENTS INITIATING AGLP1 IN 2012- REAL-LIFE STUDY BASED ON SNIIRAM DATA

    Oct 1, 2018, 00:00

  • PCV29 - REAL-WORLD DOAC AND VKA USE- THE PHARMO-ANTICOAGULATION COHORT

    Oct 1, 2018, 00:00

  • PMU108 - INTEGRATION AND PERCEPTION OF EHEALTH IN THE PRIMARY CARE SETTING

    Oct 1, 2018, 00:00

  • PDB7 - THE EFFECT OF GLYCATED HEMOGLOBIN CONTROL ON DIABETIC FOOT COMPLICATIONS

    Oct 1, 2018, 00:00

  • PHP50 - PRICE REGULATION ORDINANCE IMPACT ON REIMBURSED PRICES FOR MOSTLY PRESCRIBED MEDICINES IN BOSNIA AND HERZEGOVINA

    Oct 1, 2018, 00:00

  • PHP193 - THE USE OF MEDTECH INNOVATION BRIEFINGS (MIBS) TO ENCOURAGE IMPLEMENTATION OF INNOVATIVE TECHNOLOGIES- A REVIEW OF PUBLISHED BRIEFINGS FROM 2014-2018

    Oct 1, 2018, 00:00

  • PHP315 - HOW FREQUENTLY IS PATIENT EXPERIENCE FORMALLY ASSESSED IN HEALTH TECHNOLOGY ASSESSMENTS? RESULTS FROM A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP178 - ROLE OF SUPPLEMENTARY AND COMPLEMENTARY PRIVATE HEALTH INSURANCE IN SELECTED COUNTRIES

    Oct 1, 2018, 00:00

  • PMH72 - THE BURDEN OF SUICIDAL IDEATION IN EUROPE FROM THE PATIENT PERSPECTIVE

    Oct 1, 2018, 00:00

  • PHP68 - HOW REGULATORY PATHS FOR E-HEALTH SOLUTIONS COULD FURTHER IMPACT MARKET ACCESS IN THE UNITED STATES AND THE EUROPEAN UNION

    Oct 1, 2018, 00:00

  • PMU124 - DOES THE CHOICE OF EQ-5D-3L TARIFF MATTER FOR THE EVALUATION OF CHRONIC DISEASES? COMPARATIVE ANALYSIS OF THE POLISH, UK, SLOVENIAN AND EUROPEAN SCORES

    Oct 1, 2018, 00:00

  • PIN57 - ECONOMIC ASSESSMENT OF EFFECTIVENESS AND SAFETY OF COMMON PRACTICE PERIOPERATIVE ANTIBIOTIC PROPHYLAXIS IN A MULTIDISCIPLINARY HOSPITAL

    Oct 1, 2018, 00:00
  • «
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50 (current)
  • »